The abnormal p53 proteins expressed in CML cell lines are non-functional

Area of Science:

• Molecular Biology
• Oncology
• Hematology

Background:

• Inactivation of the p53 tumor suppressor gene occurs in 20-40% of chronic myeloid leukemia (CML) cases during blast crisis.
• A common mechanism involves p53 allele deletion and a point mutation, producing a functional mutant p53 protein.
• The role of this elevated mutant p53 protein in CML pathogenesis and neoplastic proliferation remains unclear.

Purpose of the Study:

• To investigate the cellular function of abnormal p53 proteins (mutant and truncated) in CML cell lines.
• To determine if mutant p53 protein contributes to the pathogenesis of blastic transformation or maintains neoplastic proliferation in CML.

Main Methods:

• Utilized an antisense oligonucleotide approach to specifically inhibit p53 messenger RNA (mRNA) translation.
• Assessed the impact of p53 inhibition on cell proliferation, viability, and colony formation in CML cell lines.
• Compared cell behavior in serum-free medium with and without antisense oligonucleotides.

Main Results:

• Introduction of p53 antisense oligonucleotides effectively inhibited p53 mRNA translation.
• Inhibition of p53 expression did not affect cell proliferation, viability, or colony formation.
• No change in cell doubling time was observed in the presence of antisense oligonucleotides compared to controls.

Conclusions:

• Mutant or truncated p53 proteins expressed in CML blast cells do not promote growth or support cell survival/proliferation.
• The loss of p53's tumor suppressor function, rather than the activity of mutant forms, is likely the key mechanism in CML blast crisis transition.
• These findings suggest that targeting mutant p53 may not be a viable therapeutic strategy for CML blast crisis.